NATIONAL MARROW DONOR PROGRAM
Programs
NMDP Transplant Services
TRANSPLANT: AT NMDP, WE BELIEVE EACH OF US HOLDS THE KEY TO CURING BLOOD CANCERS AND DISORDERS. AS A GLOBAL NONPROFIT LEADER IN CELL THERAPY, NMDP CREATES ESSENTIAL CONNECTIONS BETWEEN RESEARCHERS AND SUPPORTERS TO INSPIRE ACTION AND ACCELERATE INNOVATION TO FIND LIFE-SAVING CURES. WITH THE HELP OF BLOOD STEM DONORS FROM THE WORLD'S MOST DIVERSE REGISTRY AND OUR EXTENSIVE NETWORK OF TRANSPLANT PARTERS, PHYSICIANS AND CAREGIVERS, WE'RE EXPANDING ACCESS TO TREATMENT SO THAT EVERY PATIENT CAN RECEIVE THEIR LIFE-SAVING CELL THERAPY. NMDP. FIND CURES. SAVE LIVES. CURRENTLY THERE ARE MORE THAN 9 MILLION TOTAL POTENTIAL U.S. DONORS ON THE NMDP REGISTRY. NMDP FACILITATES ALL UNRELATED TRANSPLANTS IN THE U.S., ASSISTING DOCTORS IN SEARCHING MORE THAN 41 MILLION POTENTIAL DONORS WORLDWIDE. NMDP HAS FACILITATED MORE THAN 125,000 TRANSPLANTS SINCE 1987.GeographiesNot indicatedDatesOct 1, 2022 – Sep 30, 2023Source990No causes providedNo populations provided–$326.7MNMDP Research Fellowship Program
RESEARCH: RESEARCH INNOVATIONS ARE CRITICAL TO EXPANDING TREATMENT TO MORE PATIENTS AND IMPROVING OUTCOMES. EACH YEAR, NMDP Foundation IS PROUD TO INVEST IN RESEARCH THROUGH: THE AMY STRELZER MANASEVIT RESEARCH PROGRAM (AMY PROGRAM): OUR FLAGSHIP RESEARCH FELLOWSHIP, THE AMY PROGRAM FUNDS EARLY CAREER INVESTIGATORS FOCUSED ON ADVANCES IN THE PREVENTION AND TREATMENT OF POST-CELL THERAPY COMPLICATIONS (E.G., GRAFT-VERSUS-HOST-DISEASE AND INFECTION). IN 2023, WE FUNDED THE WORK OF 12 AMY SCHOLARS. AMY SCHOLARS HAVE GONE ON TO BECOME LEADERS IN THE FIELD, PURSUING SCIENTIFIC ADVANCES THAT HELP NMDP PATIENTS LIVE LONGER, HEALTHIER LIVES. SINCE 1998, NMDP FOUNDATION HAS INVESTED NEARLY $12.5 MILLION TO HELP LAUNCH THE CAREERS OF 49 YOUNG PHYSICIAN-SCIENTISTS. AFTER RECEIVING THEIR AMY SCHOLAR AWARDS, THIS GROUP HAS GONE ON TO WIN MORE THAN $250 MILLION IN SUBSEQUENT GOVERNMENT GRANT FUNDING TO PURSUE THE DISCOVERIES THAT WILL HELP PATIENTS LIVE LONGER, HEALTHIER LIVES AFTER CELL THERAPY. TODAY, THE NMDP AMY STRELZER MANASEVIT RESEARCH PROGRAM FOR THE STUDY OF POST-CELL THERAPY COMPLICATIONS IS ONE OF THE LARGEST AND MOST COVETED FELLOWSHIPS IN THE FIELD OF TRANSPLANTATION. DONOR FOR ALL: THIS SERIES OF TRANSFORMATIONAL MULTI-CENTER STUDIES ARE TESTING A NEW TRANSPLANT PROTOCOL AIMED AT MAKING MISMATCHED DONOR TRANSPLANTS SAFER AND MORE EFFECTIVE, WITH THE GOAL OF EXPANDING ACCESS TO TRANSPLANT TO THOUSANDS OF PATIENTS WHO LACK A FULLY MATCHED DONOR. ANTHONY NOLAN TRUST: PROVIDE SUPPORT TO THE ANTHONY NOLAN RESEARCH INSTITUTE TO CONTINUE DEVELOPMENT AND MAINTENANCE OF AN HLA CLASS I AND II SEQUENCE DATABASE AND PROVISION OF HLA CLASS I AND II SEQUENCE INFORMATION. NMDP'S CENTER FOR INTERNATIONAL BLOOD AND MARROW TRANSPLANT RESEARCH (CIBMTR): A PARTNERSHIP WITH THE MEDICAL COLLEGE OF WISCONSIN IS THE LEADING HUB FOR TRANSPLANT AND CELL THERAPY RESEARCH. NMDP Foundation HELPS TO FUND VARIOUS OTHER INNOVATIVE RESEARCH STUDIES LED AND MANAGED BY THE CIBMTR.GeographiesNot indicatedDatesOct 1, 2022 – Sep 30, 2023Source990No causes providedNo populations provided–$65.6MNMDP Registry Recruitment
RECRUITMENT: THE NMDP REGISTRY IS THE MOST DIVERSE LISTING OF POTENTIAL DONORS AND CORD BLOOD UNITS IN THE WORLD. EVERY SEARCH THROUGH NMDP PROVIDES PATIENTS WITH ACCESS TO MORE THAN 41 MILLION POTENTIAL ADULT DONORS AND MORE THAN 800,000 CORD BLOOD UNITS WORLDWIDE. THE BEST MATCH FOR A PATIENT IS TYPICALLY SOMEONE WHO SHARES THEIR ETHNIC BACKGROUND. IMPROVING THE ETHNIC DIVERSITY OF THE NMDP REGISTRY IMPROVES ALL PATIENTS' ODDS OF FINDING THEIR BEST MATCH, REGARDLESS OF ETHNIC BACKGROUND. PEOPLE BETWEEN THE AGES OF 18 AND 35 ARE MOST URGENTLY NEEDED. RESEARCH HAS SHOWN THAT CELLS FORM YOUNGER DONORS LEAD TO BETTER LONG-TERM SURVIVAL FOR PATIENTS. IN FY23, MORE THAN 330,000 POTENTIAL DONORS JOINED THE NMDP REGISTRY AND MORE THAN 4,200 UMBILICAL CORD UNITS WERE ADDED TO THE REGISTRY.GeographiesNot indicatedDatesOct 1, 2022 – Sep 30, 2023Source990No causes providedNo populations provided–$48.7M
Copyright 2026. All rights reserved to Chario Inc. (d.b.a. Impala)